Compare UG & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UG | NTRB |
|---|---|---|
| Founded | 1942 | 2016 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Package Goods/Cosmetics | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.5M | 36.0M |
| IPO Year | 1995 | N/A |
| Metric | UG | NTRB |
|---|---|---|
| Price | $7.38 | $2.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.3K | 8.1K |
| Earning Date | 05-11-2026 | 05-29-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $10,545,468.00 | N/A |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | $36.18 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.58 | $2.80 |
| 52 Week High | $8.78 | $8.63 |
| Indicator | UG | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 43.22 |
| Support Level | $6.90 | $2.91 |
| Resistance Level | $7.49 | $3.16 |
| Average True Range (ATR) | 0.37 | 0.11 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 21.10 | 31.95 |
United-Guardian Inc manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients, and a line of healthcare products including pharmaceuticals and medical lubricants. Its pharmaceutical products are distributed through national drug wholesalers to pharmacies, physicians, and hospitals. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. The company's majority of revenue is derived from the sales of Pharmaceuticals in the United States.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.